BCIQ Profiles

Company Profile Report

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in the

Read the full 361 word article

How to gain access

Continue reading with a
two-week free trial.